-SEC Filing
Stifel Maintains Hold on CRISPR Therapeutics, Lowers Price Target to $101
Stifel analyst Benjamin Burnett maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and lowers the price target from $139 to $101.
Related Posts
Mizuho Upgrades Oatly Group to Buy, Announces $6 Price Target
Mizuho analyst John Baumgartner upgrades Oatly Group (NASDAQ:OTLY) from Neutral to Buy and announces $6 price target.
Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis
Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening
Paya Holdings Q4 Adj. EPS $0.09 Beats $0.08 Estimate, Sales $67.10M Beat $63.99M Estimate
Paya Holdings (NASDAQ:PAYA) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.08 by 12.5 percent. This is unchanged from the same period last year. The company reported